Plain-English translation of NCT05799378 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether — a medication that has helped control lupus for many years — can be safely stopped in older patients whose disease is very stable. Researchers want to understand if continuing this medication is still necessary, or if patients can safely discontinue it without their lupus flaring up. The study will randomly assign participants to either keep taking the medication or switch to a placebo (a pill with no active ingredient) for one year, with regular check-ins to monitor their health.
While this medication has been very effective at keeping lupus under control, it can cause eye damage when used for many years. Doctors need reliable information about whether older patients with stable, well-controlled lupus can reduce their medication burden by stopping this treatment safely, or whether the risk of their lupus worsening makes continuing the medication necessary.
You likely qualify if…
You likely don't qualify if…
You will visit the research clinic every two months for one year (six visits total). At each visit, you'll bring back your empty medication bottle and diary showing how often you took it, then receive a new 90-day supply of either your regular medication or a matching placebo (you and the researchers won't know which one you're taking). The study team will check your disease activity and overall health at each visit to make sure you're doing well and watch for any signs that your lupus is becoming more active.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States